Media Contact:
Deborah Woods
+31-332541150
marketing@orbusneich.com

OrbusNeich announces launch of Teleport™ microcatheters following CE mark approval

Launch signifies expansion of company's renowned CTO portfolio

Hong Kong [Mar 9, 2018] OrbusNeich, a global company specializing in the provision of life-changing vascular solutions, has announced the launch of its first-generation microcatheters, the Teleport series, following recent CE mark approval.

The Teleport microcatheters are designed for the ultimate balance of control and tip durability during guidewire support in accessing the most complex anatomies and occluded lesions. It is available in in two versions, the Teleport and Teleport Control, both of which are built with a proprietary hybrid braiding and coil construction design with specific focus on trackability and crossability. The Teleport Control model incorporates a slightly larger diameter braid wire for extra torque, a feature which is particularly useful during retrograde approach in tight lesions and micro channels. Both models come available in catheter working lengths of 135 cm and 150 cm for antegrade and retrograde approach, respectively.

Another unique feature of the Teleport series is the dual-layer radiopaque tip which is specially designed to increase shape durability after repeated catheter cannulations in long procedures while maintaining maximum visibility for catheter positioning. All Teleport configurations are hydrophilically coated on the distal 60 cm of the catheter (including the distal leading tip) which permits smooth crossability in support of guidewire access through calcified lesions and micro channels.

"We are pleased to expand our extensive CTO portfolio to include our newest launch of the Teleport microcatheters," said Scott Addonizio, Senior Vice President and Chief Operating Officer, OrbusNeich. "OrbusNeich remains committed to providing innovative devices to our physicians and their patients, and we will strive to continue to introduce devices that address common clinical deficiencies with existing products which have been identified through our daily and routine interactions with physicians globally. We are confident our new microcatheter will address many of these deficiencies in parallel to accomplishing our corporate goal of offering the most extensive line of CTO devices".

A long-time leader in coronary artery disease treatment, in 2013 OrbusNeich launched the innovative COMBO® Dual Therapy Stent, the world's first DES with the unique biological solution for active healing to accelerate endothelial coverage and control neointimal proliferation through the combination of the proven Pro-Healing Technology with an abluminal sirolimus drug elution delivered from a bioresorbable polymer that is completely dissipated within 90 days. In November 2016 OrbusNeich launched the new generation COMBO Plus in select countries. COMBO is supported by clinical evidence from multiple studies, involving over 6,000 patients enrolled across more than 26 countries.

About OrbusNeich – Pioneers in life-changing technologies

OrbusNeich is a global pioneer in the provision of life-changing vascular solutions and offers an extensive portfolio of products that set industry benchmarks in vascular intervention. Current products are the world's first dual therapy stents, the COMBO Plus and COMBO Dual Therapy Stents, together with stents and balloons marketed under the names of Azule®, Scoreflex®, Scoreflex® NC, Sapphire® II, Sapphire® II PRO and Sapphire® II NC, as well as products to treat peripheral artery disease: the JADE and Scoreflex® PTA balloons. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Florida, USA.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to physicians in more than 60 countries. For more information visit www.OrbusNeich.com.

###